Skip Navigation
  • Text Size: A A A
  • Print
  • Email
  • Facebook
  • Tweet
  • Share

Risk Assessments

Potential risk of variant Creutzfeld-Jakob Disease (vCJD) in recipients of U.S. licensed plasma-derived products

Status of Immune Globulin Intravenous (IGIV) Products